國家衛生研究院 NHRI:Item 3990099045/7245
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912404      Online Users : 1174
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7245


    Title: Identification of targetable FGFR gene fusions in diverse cancers
    Authors: Wu, YM;Su, F;Kalyana-Sundaram, S;Khazanov, N;Ateeq, B;Cao, X;Lonigro, RJ;Vats, P;Wang, R;Lin, SF;Cheng, AJ;Kunju, LP;Siddiqui, J;Tomlins, SA;Wyngaard, P;Sadis, S;Roychowdhury, S;Hussain, MH;Feng, FY;Zalupski, MM;Talpaz, M;Pienta, KJ;Rhodes, DR;Robinson, DR;Chinnaiyan, AM
    Contributors: National Institute of Cancer Research
    Abstract: Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. After extending our assessment of FGFR rearrangements across multiple tumor cohorts, we identified additional FGFR fusions with intact kinase domains in lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation. Overexpression of FGFR fusion proteins induced cell proliferation. Two bladder cancer cell lines that harbor FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacologic inhibition in vitro and in vivo. Because of the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clinical sequencing efforts, which incorporate transcriptome analysis for gene fusions, are poised to identify rare, targetable FGFR fusions across diverse cancer types.
    Date: 2013-06
    Relation: Cancer Discovery. 2013 Jun;3(6):636-647.
    Link to: http://dx.doi.org/10.1158/2159-8290.cd-13-0050
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2159-8274&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000321614100021
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84878781242
    Appears in Collections:[Su-Fang Lin] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB23558953.pdf2299KbAdobe PDF744View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback